Unknown

Dataset Information

Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.


ABSTRACT: Integration of viral DNA into human chromosomal DNA catalyzed by HIV integrase represents the "point of no return" in HIV infection. For this reason, HIV integrase is considered a crucial target in the development of new anti-HIV therapeutic agents. We have discovered a novel HIV integrase inhibitor 1, that exhibits potent antiviral activity and a favorable metabolism profile. This paper reports on the pharmacokinetics and toxicokinetics of compound 1 and the relevance of these findings with respect to further development of this integrase-targeted antiviral agent. Oral administration of compound 1 in Sprague Dawley rats revealed rapid absorption. Drug exposure increased with increasing drug concentration, indicative of appropriate dose-dependence correlation. Compound 1 exhibited suitable

SUBMITTER: Nair V 

PROVIDER: S-EPMC4101043 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature